Mindset Pharma to Participate in Upcoming Conferences in May 2022

Rhea-AI Summary

Mindset Pharma (OTCQB: MSSTF) has announced participation in two upcoming conferences aimed at advancing psychedelic medicine research. CEO James Lanthier will present on the importance of next-generation psychedelic drugs at the 2nd Annual Psychedelic Therapeutics & Drug Development Conference on May 23, 2022, in Arlington, VA. Additionally, both Lanthier and CSO Joseph Araujo will engage in a fireside chat at the H.C. Wainwright Global Investment Conference from May 23-26, 2022, in Miami, FL. The company focuses on developing innovative psychedelic treatments for neurological and psychiatric disorders.

TORONTO, May 04, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today announced that James Lanthier, CEO, and Joseph Araujo, CSO of Mindset, will participate in two upcoming conferences:

• The 2^nd Annual Psychedelic Therapeutics & Drug Development Conference to be held at the Westin Arlington Gateway in Arlington, VA on May 23-24, 2022. Mr. Lanthier will present “The Importance of Next Generation Psychedelic Drugs in Treating Mental Health Affliction” on Monday, May 23^rd at 1:25 p.m. ET. To attend, register here.
  
  
• H.C. Wainwright Global Investment Conference to be held at the Fontainebleau Miami Beach Hotel in Miami, FL on May 23-26, 2022. Mr. Lanthier and Mr. Araujo will participate in a fireside chat with Patrick Trucchio, H.C. Wainwright Research Analyst, on Wednesday, May 25^th at 3:00 p.m. ET. To attend, register here.
  

For more information about the conferences, or to schedule a one-on-one meeting with Mindset management, please contact your appropriate representative directly, or send an email to KCSA Strategic Communications at Mindset@kcsa.com.

About Mindset Pharma Inc.
Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established in order to develop next-generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next-generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin in addition to its own proprietary compounds. The company has a co-development agreement with the McQuade Center for Strategic Research and Development for its short-duration compounds, Mindset Families 2 & 4.

For further information on Mindset, please visit our website at www.mindsetpharma.com.

For more information, please contact:

Investor Contact:
Allison Soss/Tim Regan
KCSA Strategic Communications
Email: MindSet@kcsa.com
Phone: 212-896-1267/ 347-487-6788
​​
Media Contact:
McKenna Miller
KCSA Strategic Communications
Email: MindSet@kcsa.com
Phone: 949-606-6585

Company Contact:
James Lanthier, CEO
Email: jlanthier@mindsetpharma.com

Jason Atkinson, VP, Corporate Development
Email: jatkinson@mindsetpharma.com
Phone: 416-479-4094

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

FAQ

What is the significance of Mindset Pharma's participation in the May 2022 conferences?

Mindset Pharma's participation highlights its commitment to advancing research in psychedelic medicine, particularly at the 2nd Annual Psychedelic Therapeutics & Drug Development Conference on May 23, 2022.

When will James Lanthier present at the 2nd Annual Psychedelic Therapeutics Conference?

James Lanthier will present on May 23, 2022, at 1:25 p.m. ET at the conference in Arlington, VA.

What topics will be covered at the H.C. Wainwright Global Investment Conference?

At the conference, James Lanthier and Joseph Araujo will participate in a fireside chat on May 25, 2022, discussing advancements in psychedelic drug development.

How does Mindset Pharma address mental health issues?

Mindset Pharma focuses on developing next-generation psychedelic medicines aimed at treating neurological and psychiatric disorders with unmet medical needs.

What is the stock symbol for Mindset Pharma?

Mindset Pharma trades under the stock symbol MSSTF on the OTCQB.